Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/1b Study of Pan-KRAS Inhibitor LY4066434 in KRAS-Mutant Solid Tumors
jRCT2031240563Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of LY4066434 in Nonhematologic neoplasms and carcinoma (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose-limiting toxicities (DLTs), Treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to study drug and 1 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
LY4066434
03
Conditions
Nonhematologic neoplasmscarcinoma
Beyond the preview
Go deeper on jRCT2031240563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240563.